GENMAB A/S
Tremor tracks 29 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- GMABGenmab10Calm
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Running, no new patientsPhase 372 patientsMain results: Oct 13, 2025 - GMABGenmab0Calm
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Signing up patientsPhase 3688 patientsMain results: Dec 2029 - GMABGenmab0Calm
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Running, no new patientsPhase 1/249 patientsMain results: Oct 2027 - GMABGenmab0Calm
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Running, no new patientsPhase 1/2194 patientsMain results: Dec 2027 - GMABGenmab0Calm
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Running, no new patientsPhase 1/278 patientsMain results: Sep 2027 - GMABGenmab0Calm
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Signing up patientsPhase 1/2952 patientsMain results: Dec 2028 - GMABGenmab0Calm
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Running, no new patientsPhase 1/2666 patientsMain results: Jan 2029 - GMABGenmab0Calm
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Signing up patientsPhase 3660 patientsMain results: Aug 2029 - GMABGenmab0Calm
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Signing up patientsPhase 382 patientsMain results: Sep 2027 - GMABGenmab0Calm
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Running, no new patientsPhase 3483 patientsMain results: Oct 13, 2025 - GMABGenmab0Calm
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Running, no new patientsPhase 3584 patientsMain results: Aug 18, 2026 - GMABGenmab0Calm
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Running, no new patientsPhase 1/2543 patientsMain results: Sep 30, 2027 - GMABGenmab0Calm
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Signing up patientsPhase 3960 patientsMain results: Jul 2029 - GMABGenmab0Calm
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
Signing up patientsPhase 2160 patientsMain results: Sep 2028 - GMABGenmab0Calm
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Signing up patientsPhase 2240 patientsMain results: Nov 22, 2027 - GMABGenmab0Calm
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Running, no new patientsPhase 3191 patientsMain results: Jul 30, 2027 - GMABGenmab0Calm
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Signing up patientsPhase 3600 patientsMain results: Mar 30, 2029 - GMABGenmab0Calm
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Signing up patientsPhase 1/2560 patientsMain results: May 2028 - GMABGenmab0Calm
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Running, no new patientsPhase 3699 patientsMain results: Jan 2028 - GMABGenmab0Calm
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Running, no new patientsPhase 3621 patientsMain results: Feb 2028 - GMABGenmab0Calm
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Signing up patientsPhase 3544 patientsMain results: Oct 2028 - GMABGenmab0Calm
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Not started yetPhase 3602 patientsMain results: Mar 2030 - GMABGenmab0Calm
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Running, no new patientsPhase 3900 patientsMain results: Jun 2027 - GMABGenmab0Calm
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Running, no new patientsPhase 2184 patientsMain results: Mar 2027 - GMABGenmab0Calm
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Running, no new patientsPhase 31,095 patientsMain results: Nov 2037 - GMABGenmab0Calm
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Running, no new patientsPhase 1/2350 patientsMain results: Dec 30, 2025 - GMABGenmab0Calm
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Running, no new patientsPhase 3549 patientsMain results: Dec 2029 - GMABGenmab0Calm
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Running, no new patientsPhase 2264 patientsMain results: Nov 2032 - GMABGenmab0Calm
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Running, no new patientsPhase 3379 patientsMain results: Mar 2028
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.